WallStSmart

Abbott Laboratories (ABT)vsElectromed Inc (ELMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 63044% more annual revenue ($46.59B vs $73.78M). ELMD leads profitability with a 15.3% profit margin vs 11.7%. ELMD appears more attractively valued with a PEG of 0.35. ELMD earns a higher WallStSmart Score of 70/100 (B-).

ABT

Buy

54

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 3.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

ELMD

Strong Buy

70

out of 100

Grade: B-

Growth: 8.0Profit: 8.0Value: 6.0Quality: 9.0
Piotroski: 5/9Altman Z: 5.86
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-37.5%)

Margin of Safety

-37.5%

Fair Value

$74.13

Current Price

$101.95

$27.82 premium

UndervaluedFair: $74.13Overvalued
ELMDSignificantly Overvalued (-55.2%)

Margin of Safety

-55.2%

Fair Value

$16.28

Current Price

$27.25

$10.97 premium

UndervaluedFair: $16.28Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$176.41B9/10

Large-cap with strong market position

Free Cash FlowQuality
$2.09B8/10

Generating 2.1B in free cash flow

ELMD5 strengths · Avg: 9.4/10
PEG RatioValuation
0.3510/10

Growing faster than its price suggests

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
5.8610/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
20.6%9/10

Every $100 of equity generates 21 in profit

EPS GrowthGrowth
49.0%8/10

Earnings expanding 49.0% YoY

Areas to Watch

ABT3 concerns · Avg: 3.3/10
PEG RatioValuation
1.904/10

Expensive relative to growth rate

P/E RatioValuation
33.4x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-47.5%2/10

Earnings declined 47.5%

ELMD1 concerns · Avg: 3.0/10
Market CapQuality
$226.72M3/10

Smaller company, higher risk/reward

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Free Cash Flow. Revenue growth of 13.0% demonstrates continued momentum.

Bull Case : ELMD

The strongest argument for ELMD centers on PEG Ratio, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 15.3% and operating margin at 19.7%. Revenue growth of 11.6% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.

Bear Case : ELMD

The primary concerns for ELMD are Market Cap.

Key Dynamics to Monitor

ABT profiles as a value stock while ELMD is a mature play — different risk/reward profiles.

ABT carries more volatility with a beta of 0.59 — expect wider price swings.

ABT is growing revenue faster at 13.0% — sustainability is the question.

ABT generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

ELMD scores higher overall (70/100 vs 54/100), backed by strong 15.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Electromed Inc

HEALTHCARE · MEDICAL DEVICES · USA

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high-frequency chest wall oscillation (HFCWO) therapy in lung care for patients of all ages in the United States. and internationally. The company is headquartered in New Prague, Minnesota.

Want to dig deeper into these stocks?